Friday, July 10, 2026

pharma · Interstitial Lung Disease (ILD) · Gastrointestinal Disease

ZhongShan Hospital, Fudan

ZhongShan Hospital, Fudan clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
1936 Founded
624 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
1936
Employees
624
Programs
3
Drugs
8
Patents
0
Intelligence · Clinical Programs

ZhongShan Hospital, Fudan projects

3 ClinicalTrials.gov programs sponsored by ZhongShan Hospital, Fudan.

ZhongShan Hospital, Fudan has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ACE001-RI001

    Shanghai Zhongshan Hospital

    Interstitial Lung Disease (ILD)

    phase 1 mab active

    1 trial
  2. Tocilizumab

    Shanghai Zhongshan Hospital

    Takayasu Arteritis

    approved mab active

    1 trial
  3. Norepinephrine

    Shanghai Zhongshan Hospital

    Gastrointestinal Disease

    small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ZhongShan Hospital, Fudan have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.